Men's Weekly

.

Business Telegraph

.

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis

  • Written by Telegraph Magazine
LONDON, UK - EQS Newswire - 10 June 2022 - Financial information from over 100 multinational drug companies, involving over 70,000 data points, have been accumulated over the past 35 years to create a pharmaceutical database.

All our data (sales, COGS, SG&A, R&D and other income) have been derived from annual reports, regulatory filings and company presentations, and then analysed, wherever possible, in a like-for-like manner, irrespective of how each company presents the data. This is a key differentiator to competitive products and is important because all company management teams report "adjusted", "core", or "non-GAAP" earnings to show themselves in the best possible light. However, different inclusion/exclusion criteria in the generation of these adjustments lead to distortions and variability.

Although some of the companies are multi-divisional, another key differentiator is the extraction and analysis of data for the pharmaceutical segment only. This product is unique because it analyses the individual cost components of each company over time and generates pharma industry weighted averages, allowing peer and industry comparisons to be made. It also generates individual company and industry-wide underlying operating profit (EBIT), both pre-R&D and post R&D.

Historically, data from over 100 companies has been accumulated, but industry consolidation means that just 40 are included currently, which command an estimated 76% of the global drug industry. The main exceptions are the Chinese companies where insufficient data are available on a consistent basis.

Current companies included in dataset:

pharma.png

Click here to find out more:
https://hardmanandco.com/2021-pharma-statistics-long-term-cost-underlying-ebit-analysis/

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

Entrepreneurs & Leaders

How Mobile Mechanics in Sydney Are Transforming the Lives of Busy Professionals

In a fast-paced city like Sydney, where every hour counts, finding time for car maintenance can be a challenge. For bu...

Beyond the Marker: How Modern Whiteboards Drive Team Collaboration

Collaboration in the workplace has undergone a transformation. With the rise of hybrid work models, agile project mana...

Essential Strata Insurance Services Every Multi-Owner Building Must Get Right

When multiple parties share ownership in a property, ensuring its longevity and protection demands more than just good...

Global Content Delivery with Headless CMS and Edge Networks

As the world gets more interconnected every day, businesses with international audiences now demand rapid, consistent...

How Commercial Security Systems Are Helping Sydney Businesses Reduce Insurance Costs

Running a business in Sydney isn’t cheap, from rising rent prices to staffing costs and everything in between, it’s no...

Blocked Drains Sydney: What Every Property Manager Should Know (Before It’s Too Late)

Let’s be honest—blocked drains aren’t the kind of thing anyone wants to deal with. But if you’re managing a property, ...

Design Without Designers: How AI Tools Build Visually Stunning Landing Pages

Before now, the average person would have to hire a designer, spend hours, and sometimes even require an entire creati...

Argent Biopharma (ASX:RGT) Lands European Approval — Market Reaction Begins

Most investors scroll past microcap biotech stocks, assuming they’re years away from anything real. But Argent Biophar...

SMTP Error 451: Temporary Local Problem But Is It Yours or Theirs?

SMTP error 451 is one of those frustrating mistakes that exist in a fuzzy realm between sender and receiver responsibi...